Upgrade to Pro


  • វិនិយោគទឹកប្រាក់ចាប់ពី ៤០,០០០ ដុល្លារ ដល់ ១ លានដុល្លារ
    ធ្វើការជួញដូរជាមួយខ្ញុំនៅលើ FOMO ហើយទទួលបានការបញ្ចុះតម្លៃ ១០% លើកម្រៃសេវា!
    use my referral code: sathvichet

    #bitcoin #fomo #trade #forex
    វិនិយោគទឹកប្រាក់ចាប់ពី ៤០,០០០ ដុល្លារ ដល់ ១ លានដុល្លារ ធ្វើការជួញដូរជាមួយខ្ញុំនៅលើ FOMO ហើយទទួលបានការបញ្ចុះតម្លៃ ១០% លើកម្រៃសេវា! use my referral code: sathvichet #bitcoin #fomo #trade #forex
    XTHREAD.NET
    វិនិយោគទឹកប្រាក់ចាប់ពី ៤០,០០០ ដុល្លារ ដល់ ១ លានដុល្លារ ធ្វើការជួញដូរជាមួយខ្ញុំនៅលើ FOMO ហើយទទួលបានការបញ្ចុះតម្លៃ ១០% លើកម្រៃសេវា! use my referral code: sathvichet #bitcoin #fomo #trade #forex
    Web
    1
    ·24 Views
  • អភិវឌ្ឍសមត្ថភាព​
    អភិវឌ្ឍសមត្ថភាព🤔​
    2
    ·19 Views ·1 Shares
  • ·1 Views
  • Various in vitro techniques are currently available for measuring antibody levels in human serum samples. These highly specific assays can be used to determine whether an individual has been exposed to a pathogen and to evaluate the strength, breadth and duration of vaccine-induced immunity at the individual and population levels. Multiplex (or multi-analyte) platforms are increasingly being used to evaluate immune responses to multiple antigens simultaneously, typically reducing the cost per sample and allowing more efficient use of available samples. Consequently, multiplex serological testing has become an indispensable component of numerous public health programmes. Currently, laboratories conducting HPV serological testing worldwide are limited to a small number of academic institutions, public health agencies and vaccine manufacturers.

    To support vaccine development and immunological research, CD Bioparticles now offers HPV serological multiplex immunoassay services to the research community for measuring antibody subtypes and subclasses. CD Bioparticles’ new multiplexed assay platform is ideally suited to analyzing humoral immune responses following HPV vaccination, making it particularly well-suited to epidemiological studies and vaccine immunogenicity bridging assessments.

    CD Bioparticles’ service platforms offer multiple technical advantages. For example, this high-throughput HPV serological assay can simultaneously detect antibodies against multiple HPV viral-like particles (VLPs) in a single well and is compatible with 96-well and 384-well plates. The microsphere-based multiplexed assay platform enables researchers to detect antibodies against more than seven oncogenic HPV vaccine subtypes, resulting in high sample utilization. This method shows a high correlation with HPV pseudovirus-based neutralisation assays (PBNA), and CD Bioparticles has completed comprehensive validation for total IgG, offering flexible modules suitable for IgA1/2, IgM and IgG subclasses. Additionally, CD Bioparticles supports the scalability required to evaluate other antibody properties (e.g. Fc receptor binding and complement activation).

    The HPV antibody response assessment service from CD Bioparticles has a wide range of applications, including evaluating the immunogenicity of HPV vaccines, conducting immunobridge studies for single-dose and alternative dosing regimens, performing epidemiological seroprevalence studies, comparing HPV biosimilar vaccines, monitoring antibody decline and persistence longitudinally, and analyzing subtypes and isotypes to distinguish between mucosal and systemic immune responses.

    CD Bioparticles’ new high-throughput platform offers professional support for vaccine developers, CROs, and academic partners to advance vaccine research and global public health initiatives, and enables comprehensive profiling of human papillomavirus humoral immune responses in a single, sample-efficient assay. To learn more about the HPV Serology Multiplex Immunoassay services or to request a project consultation, please visit https://www.cd-bioparticles.com/services/hpv-serology-multiplex-immunoassay.html
    Various in vitro techniques are currently available for measuring antibody levels in human serum samples. These highly specific assays can be used to determine whether an individual has been exposed to a pathogen and to evaluate the strength, breadth and duration of vaccine-induced immunity at the individual and population levels. Multiplex (or multi-analyte) platforms are increasingly being used to evaluate immune responses to multiple antigens simultaneously, typically reducing the cost per sample and allowing more efficient use of available samples. Consequently, multiplex serological testing has become an indispensable component of numerous public health programmes. Currently, laboratories conducting HPV serological testing worldwide are limited to a small number of academic institutions, public health agencies and vaccine manufacturers. To support vaccine development and immunological research, CD Bioparticles now offers HPV serological multiplex immunoassay services to the research community for measuring antibody subtypes and subclasses. CD Bioparticles’ new multiplexed assay platform is ideally suited to analyzing humoral immune responses following HPV vaccination, making it particularly well-suited to epidemiological studies and vaccine immunogenicity bridging assessments. CD Bioparticles’ service platforms offer multiple technical advantages. For example, this high-throughput HPV serological assay can simultaneously detect antibodies against multiple HPV viral-like particles (VLPs) in a single well and is compatible with 96-well and 384-well plates. The microsphere-based multiplexed assay platform enables researchers to detect antibodies against more than seven oncogenic HPV vaccine subtypes, resulting in high sample utilization. This method shows a high correlation with HPV pseudovirus-based neutralisation assays (PBNA), and CD Bioparticles has completed comprehensive validation for total IgG, offering flexible modules suitable for IgA1/2, IgM and IgG subclasses. Additionally, CD Bioparticles supports the scalability required to evaluate other antibody properties (e.g. Fc receptor binding and complement activation). The HPV antibody response assessment service from CD Bioparticles has a wide range of applications, including evaluating the immunogenicity of HPV vaccines, conducting immunobridge studies for single-dose and alternative dosing regimens, performing epidemiological seroprevalence studies, comparing HPV biosimilar vaccines, monitoring antibody decline and persistence longitudinally, and analyzing subtypes and isotypes to distinguish between mucosal and systemic immune responses. CD Bioparticles’ new high-throughput platform offers professional support for vaccine developers, CROs, and academic partners to advance vaccine research and global public health initiatives, and enables comprehensive profiling of human papillomavirus humoral immune responses in a single, sample-efficient assay. To learn more about the HPV Serology Multiplex Immunoassay services or to request a project consultation, please visit https://www.cd-bioparticles.com/services/hpv-serology-multiplex-immunoassay.html
    WWW.CD-BIOPARTICLES.COM
    Multiplex Bead-based Immunoassay for HPV Profiling - CD Bioparticles
    CD Bioparticles offers HPV serology multiplex immunoassay to measure antibody isotypes/subclasses for the performance evaluation of biosimilar candidate vaccines.
    1
    ·6 Views

  • វិនិយោគទឹកប្រាក់ចាប់ពី ៤០,០០០ ដុល្លារ ដល់ ១ លានដុល្លារ
    ធ្វើការជួញដូរជាមួយខ្ញុំនៅលើ FOMO ហើយទទួលបានការបញ្ចុះតម្លៃ ១០% លើកម្រៃសេវា!
    use my referral code: sathvichet

    #bitcoin #fomo #trade #forex
    វិនិយោគទឹកប្រាក់ចាប់ពី ៤០,០០០ ដុល្លារ ដល់ ១ លានដុល្លារ ធ្វើការជួញដូរជាមួយខ្ញុំនៅលើ FOMO ហើយទទួលបានការបញ្ចុះតម្លៃ ១០% លើកម្រៃសេវា! use my referral code: sathvichet #bitcoin #fomo #trade #forex
    XTHREAD.NET
    វិនិយោគទឹកប្រាក់ចាប់ពី ៤០,០០០ ដុល្លារ ដល់ ១ លានដុល្លារ ធ្វើការជួញដូរជាមួយខ្ញុំនៅលើ FOMO ហើយទទួលបានការបញ្ចុះតម្លៃ ១០% លើកម្រៃសេវា! use my referral code: sathvichet #bitcoin #fomo #trade #forex
    Web
    1
    ·6 Views
  • Natural products have great potential in biomedical research, drug development and clinical applications as they can be used medicinal sources to treat cancer, bacterial and fungal infections, inflammation and other diseases. These compounds in particular exhibit excellent biocompatibility, broad-spectrum biological activity and highly targeted effects, making them potent anti-cancer chemopreventive and chemotherapeutic agents with minimal side effects. Furthermore, these abundant and diverse natural sources can help to reduce the cost of cancer treatment.

    EGCG is a natural phenolic compound found in foods and beverages (particularly tea) that exhibits a wide range of biological activities, including antioxidant, antibacterial, anti-obesity, anti-inflammatory and anticancer properties. The formation of EGCG self-assembled nanoparticles (ENPs) during the oxidation process is driven by intermolecular interactions, which maintain the stability of the nanoparticles. EGCG-based nanoparticles are an excellent carrier platform for antitumour drug delivery. To support researchers' work, CD Bioparticles now offers a high-loading EGCG-based nanoparticle platform designed specifically for combined antitumour therapy and efficient drug delivery.

    CD Bioparticles offers custom, high-loading EGCG nanoparticle services to leverage advanced nanomedicine delivery technologies to achieve high loading, controlled release and targeted delivery, thereby maximizing the therapeutic potential of EGCG. The platform achieves loading rates of 30–50% (compared to 5–10% for traditional carriers), thereby increasing the effective dose while reducing the required carrier amount.

    Additionally, the platform offers broad drug compatibility and is capable of simultaneously loading both hydrophilic and hydrophobic drugs, providing an efficient platform for multi-drug combination therapy. CD Bioparticles supports anti-tumour combination therapy regimens to achieve drug synergy and improve treatment outcomes. With a particle size range of 100–200 nm, CD Bioparticles' nanoparticles enhance tumour permeability and cellular uptake.

    CD Bioparticles' comprehensive services include nanoparticle preparation customization, drug loading and capacity optimization, precise particle size and morphology characterization, stability and release performance evaluation, biocompatibility and efficacy assessment, and scalable production. These services can support researchers in various applications, such as in vitro drug screening and delivery mechanism studies, antitumour combination drug delivery, and targeted drug delivery and nanomedicine development.

    Researchers and pharmaceutical developers working in oncology, targeted nanomedicine and sustained-release systems R&D who would like to learn more about CD Bioparticles' High-Loading-Capacity EGCG Nanoparticle Development services, or who would like to discuss custom project requirements and explore available development solutions, please visit https://www.cd-bioparticles.net/services/custom-high-loading-egcg-nanoparticles-development-service.html
    Natural products have great potential in biomedical research, drug development and clinical applications as they can be used medicinal sources to treat cancer, bacterial and fungal infections, inflammation and other diseases. These compounds in particular exhibit excellent biocompatibility, broad-spectrum biological activity and highly targeted effects, making them potent anti-cancer chemopreventive and chemotherapeutic agents with minimal side effects. Furthermore, these abundant and diverse natural sources can help to reduce the cost of cancer treatment. EGCG is a natural phenolic compound found in foods and beverages (particularly tea) that exhibits a wide range of biological activities, including antioxidant, antibacterial, anti-obesity, anti-inflammatory and anticancer properties. The formation of EGCG self-assembled nanoparticles (ENPs) during the oxidation process is driven by intermolecular interactions, which maintain the stability of the nanoparticles. EGCG-based nanoparticles are an excellent carrier platform for antitumour drug delivery. To support researchers' work, CD Bioparticles now offers a high-loading EGCG-based nanoparticle platform designed specifically for combined antitumour therapy and efficient drug delivery. CD Bioparticles offers custom, high-loading EGCG nanoparticle services to leverage advanced nanomedicine delivery technologies to achieve high loading, controlled release and targeted delivery, thereby maximizing the therapeutic potential of EGCG. The platform achieves loading rates of 30–50% (compared to 5–10% for traditional carriers), thereby increasing the effective dose while reducing the required carrier amount. Additionally, the platform offers broad drug compatibility and is capable of simultaneously loading both hydrophilic and hydrophobic drugs, providing an efficient platform for multi-drug combination therapy. CD Bioparticles supports anti-tumour combination therapy regimens to achieve drug synergy and improve treatment outcomes. With a particle size range of 100–200 nm, CD Bioparticles' nanoparticles enhance tumour permeability and cellular uptake. CD Bioparticles' comprehensive services include nanoparticle preparation customization, drug loading and capacity optimization, precise particle size and morphology characterization, stability and release performance evaluation, biocompatibility and efficacy assessment, and scalable production. These services can support researchers in various applications, such as in vitro drug screening and delivery mechanism studies, antitumour combination drug delivery, and targeted drug delivery and nanomedicine development. Researchers and pharmaceutical developers working in oncology, targeted nanomedicine and sustained-release systems R&D who would like to learn more about CD Bioparticles' High-Loading-Capacity EGCG Nanoparticle Development services, or who would like to discuss custom project requirements and explore available development solutions, please visit https://www.cd-bioparticles.net/services/custom-high-loading-egcg-nanoparticles-development-service.html
    WWW.CD-BIOPARTICLES.NET
    Custom High-Loading EGCG Nanoparticles Development Service - CD Bioparticles
    CD Bioparticles provide a high drug-loading nanoparticle platform based on EGCG, specifically designed for combination antitumor therapy and efficient drug delivery.
    1
    ·6 Views
  • អភិវឌ្ឍសមត្ថភាព​
    ·3 Views
ALS Social https://als.social